Trumprx: President Donald Trump on Thursday unveiled agreements with Eli Lilly and Novo Nordisk aimed at cutting the prices of some of their obesity medications, including upcoming pills. The move is designed to make these expensive, blockbuster treatments more accessible to Americans.Trump Announcement Today: GLP-1 Drugs to Become Affordable for Medicare and Medicaid BeneficiariesThe deals will reduce costs for GLP-1 drugs for Medicare and Medicaid recipients starting in 2026. The Trump administration also plans to sell the medications directly to consumers at a discount via a new website, TrumpRx.gov, launching in January. For the first time, Medicare will cover obesity treatments, which could encourage private insurers to follow suit. Certain Medicare patients will pay just $50 per mont

See Full Page